fda compounding semaglutide crackdown september 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Beyond the Headlines: FDA Warning

Expanding the labeled indication to include OSA opened the door to payer-supported access to GLP-1 therapy for patients with obesity-associated OSA, with the potential to reduce reliance on devices

Most patients begin noticing improvements in recovery and inflammation within the first few weeks of a supervised protocol

Duracin: los efectos sobre almacenamiento muscular de carnitina requieren uso continuo de al menos 4-6 semanas para ser notables

Since 2005, multiple GLP-1R agonists resembling exendin-4 have been developed ( Figure 2 ), with fatty-acid modifications to increase half-life and facilitate less frequent dosing regimes